Présentation de l'entreprise
Quipt Home Medical Corp. operates within the healthcare sector, specifically focusing on the medical distribution industry, where it provides durable and home medical equipment and supplies throughout the United States. Through its subsidiaries, the entity delivers a comprehensive range of solutions including nebulizers, invasive ventilation systems, sleep apnea and PAP treatments, home ventilation equipment, and daily ambulatory AI-driven services. The company maintains a substantial operational footprint employing approximately 1,500 individuals to support its distribution network and service delivery. With a market capitalization of 162.30 million dollars and annual revenues totaling 264.97 million dollars, Quipt Home Medical Corp. establishes itself as a significant player in the home medical equipment market. These valuation and revenue figures indicate that the company holds a considerable position within its niche, suggesting a level of market recognition and operational scale that supports its ongoing expansion in the home medical equipment sector.
Santé financière
Quipt Home Medical Corp. reported annual revenues of 264.97 million dollars, yet generated a net income loss of 10.67 million dollars over the trailing twelve months, a disparity that highlights a challenging cost structure or significant non-operating expenses affecting the bottom line. Despite the negative net income, the company demonstrated robust operational efficiency with an EBITDA of 43.58 million dollars, indicating strong underlying cash generation capabilities before interest, taxes, depreciation, and amortization. The firm generated 44.54 million dollars in free cash flow, which provides essential financial flexibility to fund operations, manage debt obligations, or pursue strategic initiatives without relying on external capital. The company's profitability metrics are mixed, featuring a gross margin of 72.4% which reflects high efficiency in production or purchasing, contrasted by a low operating margin of 1.5% and a negative profit margin of -4.0% that signals pressure on overall profitability. On the balance sheet, Quipt holds 10.54 million dollars in cash against 115.63 million dollars in total debt, resulting in a debt-to-equity ratio of 102.33% which characterizes a highly leveraged financial structure rather than a conservative one. Liquidity is tight but manageable, evidenced by a current ratio of 1.04, suggesting the company possesses just enough current assets to cover its short-term liabilities. Return metrics further illustrate the impact of the losses, with a return on equity of -9.3% and a return on assets of -0.8%, revealing that management has not yet been effective in generating positive returns on the capital invested in the business.
Évaluation de la valorisation
The valuation metrics for Quipt Home Medical Corp. present a complex picture, with a trailing twelve-month P/E ratio that is technically not available due to the lack of earnings, while the forward P/E ratio stands at 182.50, implying that the market expects a significant turnaround in earnings or is pricing in substantial future growth. The price-to-book ratio is 1.59, indicating that the market values the company at a premium of 59% over its book value, which may reflect confidence in its intangible assets or future revenue potential despite current losses. Alternative valuation multiples such as the price-to-sales ratio of 0.61 and an EV/EBITDA of 6.41 suggest that the company is valued at a discount relative to its sales and earnings power, potentially making it attractive if the current loss position is temporary. The stock's price volatility is contained relative to the broader market, as indicated by a beta of 0.49, suggesting that the share price is less sensitive to general market movements. Over the past year, the stock traded between a low of 1.35 dollars and a high of 3.65 dollars, providing a clear context for the current trading price relative to its historical range.
Growth & Income
Quipt Home Medical Corp. has demonstrated impressive revenue expansion with a year-over-year growth rate of 32.0%, while earnings growth is not available due to the reported net losses, indicating that revenue expansion has not yet translated into profitability. The company does not pay dividends, as evidenced by a dividend yield of not available and a payout ratio of 0.0%, meaning that all available earnings and free cash flow are reinvested into the business to fuel growth and pay down debt rather than being distributed to shareholders. The combination of high revenue growth and a lack of current profitability suggests a growth-stage profile where the company prioritizes market share acquisition and operational scaling over immediate income generation. Overall, the growth and income profile is characterized by rapid top-line expansion supported by strong cash flow, albeit without current dividend support or positive earnings, positioning the stock as a high-risk, high-potential growth play within the medical distribution sector.